CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

CureVac N.V., a biopharmaceutical company specializing in mRNA technology, announced the appointment of Thaminda Ramanayake as its new Chief Business Officer, starting from June 1, 2024. Ramanayake has over fifteen years of experience in the biopharmaceutical sector, with a focus on corporate strategy, business development, and strategic partnerships. His prior role was with Affini-T Therapeutics, where he formed the business development organization. He also held significant positions at Sanofi and BioMarin Pharmaceuticals, contributing to several high-value collaborations and asset acquisitions.

Dr. Alexander Zehnder, CureVac's CEO, highlighted Ramanayake's extensive experience in advancing corporate strategy and business development. He praised Ramanayake's leadership and advisory skills, which are expected to drive the company's future mRNA vaccine and medicine developments in areas like infectious diseases and oncology. Ramanayake himself expressed enthusiasm for joining CureVac amidst promising developments in its vaccine programs, emphasizing the transformative potential of mRNA technology.